Depo-Provera and Meningioma Litigation: What Attorneys Need From Medical Experts

Depo-Provera and meningioma litigation has become one of the fastest-growing mass torts in the country. As of the July 1, 2026 JPML statistics report, 5,830 cases are pending in MDL No. 3140 in the Northern District of Florida, with 5,916 total historical actions filed. Plaintiffs allege that Pfizer’s injectable contraceptive caused meningiomas, a type of brain tumor that forms in the membranes surrounding the brain. With a global settlement framework now in place and Rule 702 proceedings still relevant for non-settling claims, the demand for qualified neurosurgery, neuroradiology, and OB/GYN expert witnesses continues to grow.

The Litigation Landscape

The Depo-Provera meningioma MDL has grown at an extraordinary pace since its creation. The Judicial Panel on Multidistrict Litigation centralized the cases in the Northern District of Florida in February 2025, assigning them to U.S. District Judge M. Casey Rodgers. Since then, the docket has expanded from fewer than 100 initial actions to nearly 6,000 in roughly 18 months.¹ Plaintiffs allege that Pfizer Inc., Pharmacia LLC, and Pharmacia & Upjohn Co. LLC failed to adequately warn consumers and prescribers that long-term use of Depo-Provera (depot medroxyprogesterone acetate, or DMPA) was associated with an increased risk of developing meningiomas. The core of the failure-to-warn theory is that the manufacturers had access to scientific evidence linking progestins to meningioma growth for years before the product label reflected that risk. In December 2025, the FDA approved a label change for Depo-Provera adding a meningioma warning under Section 5.4 of the prescribing information. The updated label states that meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use, and directs prescribers to discontinue the drug if a meningioma is diagnosed.² Plaintiffs contend that this warning came too late and that the manufacturers had sufficient data to update the label years earlier. On June 15, 2026, Judge Rodgers issued Pretrial Order No. 30A confirming that plaintiffs’ lead counsel and the defendants had reached a global settlement agreement in principle for eligible claims pending in the MDL.³ The parties signed a formal Master Settlement Agreement on July 21, 2026. The court has indicated that approximately 80 percent of the plaintiffs currently in the federal MDL are estimated to be eligible for the settlement, though no financial terms, payout tiers, or eligibility criteria have been publicly disclosed.⁴ The settlement agreement prompted several significant procedural changes. Judge Rodgers vacated the first bellwether trial, Toney v. Pfizer, which had been scheduled for December 7, 2026. She also reset the general causation Rule 702/Daubert evidentiary hearing from its original June 24 to 25 date to July 27, 2026. On July 28, the court entered Case Management Order No. 12, which addressed settlement administration procedures and ongoing state court litigation coordination.⁵ The settlement does not resolve all claims. Cases that fall outside the agreement’s eligibility criteria, along with state court actions, will continue through litigation. The court has maintained a Rule 702 hearing on its calendar for September 18, 2026, which remains relevant for claims that are not covered by the settlement.⁶ In addition to the federal MDL, related cases have been consolidated in state courts in New York (before Justice Sabrina Kraus), Delaware (before Judge Kathleen Vavala), and California (Alameda County coordinated proceedings). Pfizer’s defense centers on two primary arguments. First, the company has filed a motion for summary judgment based on federal preemption, arguing that FDA regulations governing the drug’s labeling preempt state law failure-to-warn claims. Second, Pfizer has challenged the admissibility of plaintiffs’ general causation experts under Rule 702, seeking to exclude testimony linking DMPA to meningioma development.⁷

The Injuries at Issue

The central injury alleged in MDL 3140 is meningioma, a tumor that arises from the meninges, the protective membranes that surround the brain and spinal cord. While meningiomas are classified as the most common primary intracranial tumor and are typically slow-growing and histologically benign (WHO Grade I), they can cause serious and lasting harm depending on their size, number, and location. Skull Base and Deep-Seated Meningiomas Published research on DMPA-associated meningiomas has identified a distinctive pattern. These tumors are disproportionately located at the skull base, including the cavernous sinus and the planum sphenoidale, areas where surgical access is more complex and the risk of damage to critical neurovascular structures is significantly higher.⁸ The cavernous sinus houses the internal carotid artery and multiple cranial nerves controlling eye movement, facial sensation, and other functions. Tumors in this location may be inoperable or require multiple staged procedures with elevated complication rates. Multiple Meningiomas DMPA-associated meningiomas are significantly more likely to present as multiple tumors compared to sporadic meningiomas. In the published literature, roughly half of DMPA-linked cases involved multiple meningiomas, compared to approximately 17 percent in the general meningioma population.⁸ Multiple tumors increase the complexity of treatment planning, the number of required surgeries, and the cumulative neurological risk. Symptoms and Clinical Presentation Meningioma symptoms depend on tumor location and typically develop gradually. Plaintiffs in this litigation allege symptoms including:

• Persistent headaches that worsen over time, often more severe in the morning
• Vision changes, including blurred vision, double vision, and loss of peripheral vision, particularly with skull base tumors compressing the optic nerves
• Seizures, especially with convexity meningiomas pressing on the cerebral cortex
• Cognitive difficulties, including memory problems and personality changes
• Hearing loss or tinnitus with tumors near the cerebellopontine angle
• Weakness or numbness in the extremities

Treatment and Long-Term Impact Treatment for meningioma typically involves surgical resection (craniotomy), stereotactic radiosurgery, or a combination. Some patients require multiple surgeries, particularly when tumors recur or when the initial resection was subtotal due to the tumor’s proximity to critical brain structures. Recurrence rates depend on the histological grade and the completeness of resection. Plaintiffs allege lasting injuries including permanent neurological deficits, cognitive impairment, chronic seizure disorders, vision loss, and the ongoing need for surveillance imaging. Progesterone Receptor Expression A critical biological feature of DMPA-associated meningiomas is their near-universal expression of progesterone receptors. In one published case series, 100 percent of DMPA-linked meningiomas tested positive for progesterone receptor expression, compared to a lower rate in sporadic tumors.⁸ This finding supports the biological plausibility of a causal link between prolonged progestin exposure and meningioma growth, and it is expected to be central to the general causation testimony in this litigation.

The Science Behind the Claims

The scientific evidence linking depot medroxyprogesterone acetate to meningioma risk has grown substantially in recent years. Several large epidemiological studies and a systematic meta-analysis now form the evidentiary foundation for plaintiffs’ general causation case. The French National Case-Control Study (BMJ, 2024) A large French case-control study published in the BMJ in March 2024 examined the association between progestogen use and intracranial meningioma. The study found that prolonged use of injectable medroxyprogesterone acetate was associated with an increased risk of intracranial meningioma. The authors noted that this finding was particularly significant because DMPA is one of the most widely used injectable contraceptives globally.⁹U.S. Propensity Score-Matched Cohort Study (JAMA, 2025) A U.S.-based cohort study published in JAMA in November 2025 used propensity score matching to compare meningioma risk in DMPA users versus non-users. After matching 88,667 patients with a mean age of 26.2 years, the study found that depot medroxyprogesterone acetate use was associated with a relative risk of 2.43 (95% CI, 1.77 to 3.33) for meningioma.¹⁰Swedish Register-Based Case-Control Study (Neuro-Oncology, 2025) A Swedish case-control study published in Neuro-Oncology in October 2025 reported an odds ratio of 5.49 (95% CI, 4.51 to 6.67) for meningioma among users of contraceptives containing medroxyprogesterone. The association was substantially stronger for medroxyprogesterone than for other progestogen-containing contraceptives, which had a weaker odds ratio of 1.34.¹¹Systematic Review and Meta-Analysis (Cancers, April 2026) A meta-analysis published in Cancers in April 2026 pooled data from nine case-control studies and one cohort study. The overall pooled odds ratio for the association between DMPA exposure and cerebral meningioma was 2.78 (95% CI, 2.20 to 3.52). The association was strongest for prolonged exposure of two years or more, with a pooled odds ratio of 3.49.¹²DMPA Tumor Pattern Study (Neurosurgery, April 2026) A study published in Neurosurgery in April 2026 examined the anatomical and pathological pattern of DMPA-associated meningiomas compared to sporadic meningiomas. DMPA-linked tumors were significantly more likely to be multiple (50.0% versus 17.5%), were disproportionately located in the cavernous sinus (39.5% versus 15.8%) and planum sphenoidale (21.1% versus 7.0%), and demonstrated universal progesterone receptor expression (100%).⁸Neuro-Oncology Review (May 2026) A review article published in Neuro-Oncology in May 2026 summarized the epidemiological and clinical evidence linking DMPA to meningioma. The authors concluded that DMPA exposure increases the risk of meningioma by 1.5- to 5.5-fold, though they noted that the absolute risk remains small.¹³ Taken together, this body of evidence provides the epidemiological, clinical, and biological basis that plaintiffs will rely on for general causation testimony. The dose-response relationship (higher risk with longer exposure), the biological mechanism (progesterone receptor-mediated tumor growth), and the distinctive tumor pattern (skull base, multiple, universally PR-positive) all contribute to the causation framework.

Why Expert Witnesses Are Critical

Whether cases proceed through the settlement process or continue to contested litigation, expert witnesses play a central role. For settling claims, experts may be needed to document the nature and severity of injuries for compensation tier classification. For non-settling claims headed toward Daubert hearings and potential trial, expert testimony on both general and specific causation is essential. This MDL demands expertise across multiple medical specialties. Neurosurgery Experts Neurosurgeons are at the center of this litigation because meningioma treatment almost always involves a neurosurgical evaluation, and frequently requires surgical intervention. Neurosurgery experts are needed to:

• Explain the surgical complexity of skull base meningiomas, particularly tumors in the cavernous sinus, sphenoid wing, and planum sphenoidale
• Testify on the risks and outcomes of craniotomy for meningioma resection, including the likelihood of subtotal resection in deep-seated locations
• Describe the clinical decision-making process for surgical versus conservative management (watch-and-wait surveillance)
• Address recurrence rates by tumor grade and extent of resection, and the implications for future surgeries
• Opine on the long-term neurological consequences of the tumor itself and of surgical intervention, including deficits in vision, cranial nerve function, and cognition
• Evaluate whether a plaintiff’s specific meningioma presentation is consistent with the DMPA-associated tumor pattern described in the published literature

Neuroradiology Experts Neuroradiologists interpret the brain MRI and CT imaging that is foundational to diagnosis, surgical planning, and surveillance. Neuroradiology experts are needed to:

• Authenticate and interpret diagnostic imaging showing meningioma size, location, number, and growth rate over time
• Distinguish meningioma from other intracranial masses based on imaging characteristics
• Identify the skull base and deep-seated tumor patterns that published research associates with DMPA use
• Establish timelines of tumor growth relative to the period of DMPA administration by reviewing serial imaging studies
• Assess whether the radiological features of a plaintiff’s tumor(s) are consistent with hormone-driven meningioma growth
• Provide imaging-based evidence for cases involving multiple meningiomas, a hallmark of the DMPA-associated presentation

OB/GYN (Obstetrics and Gynecology) Experts OB/GYNs prescribed Depo-Provera and are the clinicians most familiar with its use in reproductive health. OB/GYN experts are needed to:

• Testify about prescribing practices for DMPA as a contraceptive, including duration of use, patient selection, and informed consent standards
• Address the adequacy of the manufacturer’s warnings to prescribers prior to the December 2025 label update
• Explain the standard of care for monitoring patients on long-term DMPA therapy and whether meningioma screening was indicated
• Opine on whether an earlier label warning would have changed prescribing behavior or prompted referral for neuroimaging
• Discuss alternative contraceptive options that were available to patients and whether adequate risk-benefit counseling occurred
• Provide context on the duration and frequency of DMPA use in individual plaintiffs’ medical histories

Additional Specialties Depending on the specific case, attorneys may also need:

• Neuropathology experts to testify on tumor histology, WHO grading, and progesterone receptor expression in resected specimens
• Pharmacology and toxicology experts to address general causation, the dose-response relationship between DMPA exposure and meningioma risk, and the biological plausibility of progesterone receptor-mediated tumor growth
• Neuro-oncology experts to address treatment planning, prognosis, and the clinical significance of recurrence in both surgically treated and conservatively managed meningiomas

What Attorneys Should Look for in Expert Selection

Mass tort pharmaceutical litigation demands experts who can hold up under aggressive cross-examination and survive Rule 702 challenges. Attorneys evaluating experts for Depo-Provera meningioma cases should consider: For neurosurgery experts:

• Board certification in neurological surgery with active or recent clinical practice in meningioma surgery
• Specific surgical experience with skull base meningiomas, including cavernous sinus and planum sphenoidale tumors
• Published research or academic presentations on meningioma management, outcomes, or hormone-associated brain tumors
• Prior expert witness experience in pharmaceutical or medical device litigation

For neuroradiology experts:

• Board certification in diagnostic radiology with fellowship training or subspecialty practice in neuroradiology
• Experience interpreting brain MRI and CT studies for meningioma diagnosis and surveillance
• Familiarity with the imaging characteristics that distinguish hormone-associated meningiomas from sporadic tumors
• Ability to construct imaging-based timelines linking tumor detection and growth to the period of drug exposure

For OB/GYN experts:

• Board certification in obstetrics and gynecology with clinical prescribing experience for DMPA
• Understanding of the regulatory and labeling history of Depo-Provera, including the timeline of the meningioma warning
• Ability to speak to the standard of care for patient counseling, risk disclosure, and monitoring during long-term injectable contraceptive use
• Experience with case-specific causation analysis in pharmaceutical litigation

Key Dates Attorneys Should Know

Date	Event
February 2025	JPML centralizes Depo-Provera meningioma cases into MDL 3140 (N.D. Fla.)
December 2025	FDA approves updated Depo-Provera label adding meningioma warning (Section 5.4)
January 27, 2026	Court enters PTO 30, establishing procedures for preemption and Rule 702 rulings to apply across all individual actions
June 15, 2026	PTO 30A issued: global settlement agreement in principle announced; bellwether trial (Toney v. Pfizer, Dec. 7, 2026) vacated; Rule 702 hearing reset from June 24 to July 27
July 1, 2026	JPML reports 5,830 pending actions and 5,916 total actions in MDL 3140
July 21, 2026	Parties sign formal Master Settlement Agreement
July 28, 2026	CMO 12 entered: settlement administration procedures and state court coordination updates
September 18, 2026	Rule 702 hearing on general causation (for non-settling claims)
Ongoing	New cases filing monthly; state court proceedings continuing in NY, DE, CA

The settlement process is now underway, but the litigation is far from over. Attorneys representing plaintiffs whose claims may fall outside the settlement’s eligibility criteria, or who are weighing whether to opt in, need their expert teams in place now. The September 2026 Rule 702 hearing will be a critical gatekeeping event for claims that proceed to contested litigation.

How Med Legal Pro Supports Depo-Provera Litigation

Med Legal Pro connects attorneys with rigorously vetted neurosurgery, neuroradiology, and OB/GYN expert witnesses who understand the science and clinical realities behind Depo-Provera meningioma litigation. Our experts are matched to the specific demands of each case, not pulled from a generic database. Whether you need a neurosurgeon to address the surgical complexity of a skull base meningioma, a neuroradiologist to interpret imaging evidence and establish a growth timeline, or an OB/GYN to testify on prescribing practices and the adequacy of manufacturer warnings, Med Legal Pro provides:

• Expert witness matching tailored to your case type and jurisdiction
• Case pre-screening to evaluate the strength of a Depo-Provera meningioma claim before committing resources
• Medical record review and chronology to build the clinical timeline supporting causation
• C.L.E.A.R. Method™ expert reports designed for clarity and courtroom durability

With the settlement process underway and Rule 702 proceedings approaching for non-settling claims, the attorneys who secure qualified expert support now will be positioned for the strongest outcomes. Contact Med Legal Pro to discuss your Depo-Provera case or request an expert consultation. 📞 (844) 633-5345 | ✉ experts@medlegalpro.com | 🌐 medlegalpro.com Med Legal Pro LLC provides medical-legal litigation support to attorneys in personal injury, nursing home negligence, wrongful death, and mass tort cases nationwide. Medical Experience | Legal Knowledge | Professional Results.

Sources

¹ Judicial Panel on Multidistrict Litigation, JPML Statistics Report (July 1, 2026). MDL 3140, In Re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, N.D. Fla. Available at jpml.uscourts.gov. ² FDA, Highlights of Prescribing Information, Depo-Provera CI (medroxyprogesterone acetate) injectable suspension, Revised 12/2025. Warnings and Precautions, Section 5.4 (Meningioma). Available at labeling.pfizer.com. See also NBC News coverage (December 16, 2025). ³ Pretrial Order No. 30A, In Re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, MDL No. 3140, No. 3:25-md-03140-MCR-HTC (N.D. Fla. June 23, 2026). Available at flnd.uscourts.gov. ⁴ Lawsuit Information Center, Depo Provera Lawsuit Settlement, August 2026 Litigation Update. Reporting that the parties signed the Master Settlement Agreement on July 21, 2026, with approximately 80% of MDL plaintiffs estimated eligible. Available at lawsuit-information-center.com. ⁵ Case Management Order No. 12, In Re: Depo-Provera Products Liability Litigation, MDL No. 3140 (N.D. Fla. July 28, 2026). See orders index at flnd.uscourts.gov. ⁶ Lawmonarch, Depo Provera Lawsuit Meningioma Risk and Latest Court Update (July 18, 2026). Available at lawmonarch.com. ⁷ Pfizer Inc., Pharmacia LLC, and Pharmacia & Upjohn Co. LLC’s Motion for Summary Judgment Based on Federal Preemption, ECF No. 413 (N.D. Fla. Aug. 22, 2025). Available at courtlistener.com. ⁸ Pattern of Intracranial Meningiomas Associated With Prolonged DMPA Use: Systematic Review of Synthetic Progestins and Case Series of DMPA-Associated Intracranial Meningiomas. Neurosurgery. 2026. doi: 10.1227/neu.0000000000004031. ⁹ Froelich S, et al. Use of progestogens and the risk of intracranial meningioma: national case-control study. BMJ. 2024;384:e078078. doi: 10.1136/bmj-2023-078078. ¹⁰ Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US. JAMA. 2025. PubMed ID: 40892397. ¹¹ Hormonal contraceptives and the risk of meningioma: A Swedish register-based case-control study. Neuro-Oncology. 2025. doi: 10.1093/neuonc/noaf228. ¹² A Systematic Review and Meta-Analysis of the Association Between Depot Medroxyprogesterone Acetate and Cerebral Meningioma. Cancers. 2026;18(8):1252. doi: 10.3390/cancers18081252. ¹³ Epidemiological and clinical data link depot medroxyprogesterone acetate to meningioma. Neuro-Oncology. 2026. doi: 10.1093/neuonc/noag115.